Jove
Visualize
Contact Us

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

939
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
939
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

622
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
622
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

736
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
736
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

880
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
880
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
459
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Tissue And Stool Microbiome In Pediatric Inflammatory Bowel Disease Patients: Diversity Differs In Patients With Relapsing And Non-relapsing Crohn's Disease.
  1. Home
  3. Tissue And Stool Microbiome In Pediatric Inflammatory Bowel Disease Patients: Diversity Differs In Patients With Relapsing And Non-relapsing Crohn's Disease.

Related Experiment Video

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K

Tissue and stool microbiome in pediatric inflammatory bowel disease patients: diversity differs in patients with

Matěj Hrala1, Tereza Deissová1,2, Petr Andrla1

  • 1Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic.

Gut Pathogens
|November 15, 2025

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
BarnesiellaCrohn's diseaseMicrobiomePediatric inflammatory bowel diseasePrognostic marker

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

394

Related Experiment Videos

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.6K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.3K
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

394

Microbial markers in tissue and stool can predict relapse in pediatric Crohn's disease (pCD). This discovery aids in developing personalized treatments for pediatric inflammatory bowel diseases (pIBD).

Area of Science:

  • Microbiome research
  • Pediatric gastroenterology
  • Inflammatory Bowel Disease (IBD) genetics

Background:

  • Pediatric inflammatory bowel diseases (pIBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic conditions with frequent relapses.
  • Approximately 30% of pediatric IBD cases experience relapse within a year of diagnosis, necessitating prognostic markers for optimized treatment.
  • Current research lacks robust markers to predict relapse in pediatric IBD patients.

Purpose of the Study:

  • To analyze the tissue microbiome in pediatric IBD patients.
  • To identify microbial prognostic markers for disease relapse.
  • To validate the predictive power of these markers in non-invasive fecal samples.

Main Methods:

  • 16S rRNA gene sequencing was used to characterize the tissue and fecal microbiome in a prospective cohort of pediatric CD, pediatric UC, and non-IBD controls.
  • Relapse was monitored for one year post-diagnosis.
  • Receiver Operating Characteristic (ROC) analysis was employed to assess the predictive value of microbial taxa and clinical scores.

    • Main Results:

    • Relapsing pediatric CD patients showed decreased alpha diversity and altered beta diversity in tissue samples compared to non-relapsing patients.
    • The bacterial genus Barnesiella was significantly depleted in the tissue of relapsing pediatric CD patients.
    • Barnesiella, Butyricimonas, and Collinsella were identified as tissue microbial markers for pediatric CD relapse, with Barnesiella showing high prognostic power (AUC=0.818).
    • Combining Barnesiella with the weighted Pediatric Crohn's Disease Activity Index (wPCDAI) improved predictive accuracy in both tissue (AUC=0.872) and fecal samples (AUC=0.852).

    Conclusions:

    • Tissue and fecal microbial markers demonstrate high prognostic power for predicting relapse in pediatric CD patients.
    • These findings support the development of non-invasive prognostic tools for pediatric IBD.
    • The identified markers provide a foundation for precision medicine and personalized treatment strategies in pediatric IBD.